Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOLTAIRE-AI: BI 695501 Autoinjector vs Prefilled Syringe PK Study
NCT02606903Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2015
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of adalimumab in rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA) and 4 more (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Measured Concentration of BI 695501 in Plasma, Area Under the Concentration-time Curve of BI 695501 in Plasma Over Time Interval 0 to 1032 Hours and 1 more. Started Oct 2015; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)juvenile idiopathic arthritis (JIA)psoriatic arthritis (PsA)ankylosing spondylitis (AS)Crohn's disease
Beyond the preview
Go deeper on NCT02606903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02606903.